sb 203580 has been researched along with azomycin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (azomycin) | Trials (azomycin) | Recent Studies (post-2010) (azomycin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 4,790 | 418 | 1,580 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agler, ML; Chen, T; Dickson, JK; Feyen, JH; Huang, J; Knapp, AC; Lawrence, RM; Lynch, JS; Wu, Y | 1 |
1 other study(ies) available for sb 203580 and azomycin
| Article | Year |
|---|---|
High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
Topics: Acid Phosphatase; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression; Humans; Imidazoles; Isoenzymes; Lipopolysaccharides; Luciferases; Nitroimidazoles; Osteoclasts; Osteoprotegerin; Pyridines; RANK Ligand; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Tumor Necrosis Factor-alpha | 2006 |